ATR

ANEEL™ Fuel Irradiation Begins in the Advanced Test Reactor at Idaho National Lab

Retrieved on: 
Monday, April 1, 2024
Principal, PIE, Idaho National Laboratory, Face, PHWR, INL, Climate, Strategic partnership, ATR, Private sector, ANEEL, Thorium, Nuclear energy, HALEU, DOE, Core, Advanced Test Reactor, Uranium mining

CHICAGO, April 01, 2024 (GLOBE NEWSWIRE) -- Clean Core Thorium Energy (Clean Core) announced today that the accelerated irradiation testing and qualification of their patented ANEEL™ Fuel is set to begin in the Advanced Test Reactor (ATR) at the Idaho National Laboratory (INL). The fuel, made of thorium and high-assay low-enriched uranium (HALEU), was developed by Clean Core for use in pressurized heavy water reactors (PHWRs) and Canada deuterium uranium (CANDU) reactors. Its insertion into one of the US government’s premier material testing facilities represents a key milestone in the company’s multi-year, multimillion-dollar joint effort with the US Department of Energy (DOE) to design, fabricate, and assemble the irradiation experiment.

Key Points: 
  • CHICAGO, April 01, 2024 (GLOBE NEWSWIRE) -- Clean Core Thorium Energy (Clean Core) announced today that the accelerated irradiation testing and qualification of their patented ANEEL™ Fuel is set to begin in the Advanced Test Reactor (ATR) at the Idaho National Laboratory (INL).
  • In 2022, Clean Core signed a Strategic Partnership Project Agreement with INL to design and execute an irradiation experiment in ATR to demonstrate and assess the performance of Clean Core’s innovative Advanced Nuclear Energy for Enriched Life (ANEEL™) fuel.
  • Upon receipt, INL developed the irradiation test plan, performed pre-irradiation characterization of the fuel pellets, designed and fabricated the experiment hardware and test trains, assembled the test trains, and finally inserted the experiment into the ATR.
  • “Clean Core is focused on the efficient development and deployment of the ANEEL fuel in heavy water reactors, without any modifications to the fuel bundle geometry or the reactor.

Aprea Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides a Business Update

Retrieved on: 
Tuesday, March 26, 2024
Ovarian cancer, Cyclin, IND, Therapy, Anemia, Research, University, Cell cycle, MD Anderson Cancer Center, PLK1, DDR, Investigational New Drug, Safety, Pharmacokinetics, Synthetic lethality, WEE1, U.S. FDA, Mutation, Acceleration, Part, HERG, ATR, KOL, Acquisition, Cancer, AACR, Research and development, Poster, FDA, Cyclin E, Toxicity, Aplastic anemia, Administration, Conference, APRE, PLK3, PLK2, Division, Data, Cardiotoxicity, Pharmaceutical industry

DOYLESTOWN, Pa., March 26, 2024 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical-stage biopharmaceutical company focused on precision oncology through synthetic lethality, today reported financial results for the fourth quarter and full year ended December 31, 2023, and provided a business update.

Key Points: 
  • “Aprea had a very productive 2023 with significant progress across our diversified pipeline of synthetic lethality-based cancer therapeutics.
  • An update from Part 1 of the trial was featured in a poster presentation at the AACR-NCI-EORTC International Conference in October 2023.
  • Select Financial Results for the Fourth Quarter ended December 31, 2023
    As of December 31, 2023, Aprea reported cash and cash equivalents of $21.6 million.
  • Research and Development (R&D) expenses were $2.0 million for the quarter ended December 31, 2023, compared to $0.5 million for the fourth quarter of 2022.

Willis Lease Finance Corporation Completes Delivery of 4th ATR 72-500 Aircraft under its ConstantThrust® Engine Maintenance Program

Retrieved on: 
Thursday, March 21, 2024
Tax, Pratt & Whitney, Part, ATR, FBO, TAG Airlines, Security (finance), TAG, Aircraft, WLFC, Airline

COCONUT CREEK, Fla., March 21, 2024 (GLOBE NEWSWIRE) -- Willis Lease Finance Corporation (NASDAQ: WLFC) (“WLFC”) announces it has successfully delivered its fourth ATR 72-500 aircraft to Transportes Aéreos Guatemaltecos (TAG Airlines) (“TAG”) as part of its lease agreements with the airline for four ATR 72-500 aircraft.

Key Points: 
  • COCONUT CREEK, Fla., March 21, 2024 (GLOBE NEWSWIRE) -- Willis Lease Finance Corporation (NASDAQ: WLFC) (“WLFC”) announces it has successfully delivered its fourth ATR 72-500 aircraft to Transportes Aéreos Guatemaltecos (TAG Airlines) (“TAG”) as part of its lease agreements with the airline for four ATR 72-500 aircraft.
  • Under the lease agreements, the aircraft are included in WLFC’s ConstantThrust® program for PW127M engines.
  • “We are thrilled to support TAG, our first regional ConstantThrust® airline partner, with a fourth aircraft delivery,” said Austin C. Willis, Chief Executive Officer of WLFC.
  • Willis Lease Finance Corporation (“WLFC”) leases large and regional spare commercial aircraft engines, auxiliary power units and aircraft to airlines, aircraft engine manufacturers and maintenance, repair, and overhaul providers worldwide.

Repare Therapeutics Inc. (RPTX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings

Retrieved on: 
Thursday, March 21, 2024
Class Action Lawsuit, Professional Services, Legal, ATR, News

Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Repare Therapeutics Inc. (“Repare” or “the Company”) (NASDAQ: RPTX).

Key Points: 
  • Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Repare Therapeutics Inc. (“Repare” or “the Company”) (NASDAQ: RPTX).
  • Investors who purchased Repare securities are encouraged to obtain additional information and assist the investigation by visiting the firm’s site: bgandg.com/RPTX .
  • You can also contact Peretz Bronstein or his law clerk and client relations manager, Yael Nathanson of Bronstein, Gewirtz & Grossman, LLC: 332-239-2660.
  • Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits.

Aptar Named a CDP Supplier Engagement Leader for the Fourth Consecutive Year

Retrieved on: 
Wednesday, March 20, 2024
General Health, Professional Services, Pharmaceutical, Sustainability, Recycling, Environment, Green Technology, Packaging, Climate Change, Environmental, Social and Governance (ESG), Manufacturing, Health, Carbon, CDP, Climate change, Innovation, ATR, Disclosure, Plastic, AptarGroup, Multimedia

AptarGroup, Inc. (NYSE: ATR), a global leader in drug and consumer product dosing, dispensing and protection technologies, was named to the CDP Supplier Engagement Leaderboard, for the fourth consecutive year.

Key Points: 
  • AptarGroup, Inc. (NYSE: ATR), a global leader in drug and consumer product dosing, dispensing and protection technologies, was named to the CDP Supplier Engagement Leaderboard, for the fourth consecutive year.
  • View the full release here: https://www.businesswire.com/news/home/20240320103929/en/
    Graphic: Aptar is a 2023 CDP Supplier Engagement Leader (Graphic: Business Wire)
    CDP evaluates an organization’s engagement with their suppliers on climate change.
  • By evaluating supplier engagement and recognizing best practice, CDP aims to accelerate global action on supply chain emissions.
  • “Our fourth consecutive year as a CDP Supplier Engagement Leader reflects the strong collaboration between our Sustainability, Innovation and Purchasing teams where we strategically align with suppliers that are participating in our Supplier Screening process through platforms like EcoVadis,” said Beth Holland, Aptar’s Chief Sustainability Officer.

Repare Therapeutics Inc. (RPTX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings

Retrieved on: 
Friday, March 15, 2024
Class Action Lawsuit, Professional Services, Legal, ATR, News

Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Repare Therapeutics Inc. (“Repare” or “the Company”) (NASDAQ: RPTX).

Key Points: 
  • Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Repare Therapeutics Inc. (“Repare” or “the Company”) (NASDAQ: RPTX).
  • Investors who purchased Repare securities are encouraged to obtain additional information and assist the investigation by visiting the firm’s site: bgandg.com/RPTX .
  • You can also contact Peretz Bronstein or his law clerk and client relations manager, Yael Nathanson of Bronstein, Gewirtz & Grossman, LLC: 332-239-2660.
  • Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits.

Global Low Carbon (Green, Blue) Ammonia Industry Research 2024: Focus on United States, Canada, Brazil, Germany, United Kingdom, France, China, Japan, South Korea, and India 2022-2032 - ResearchAndMarkets.com

Retrieved on: 
Tuesday, March 12, 2024
Chemicals, Plastics, Agriculture, Natural Resources, Manufacturing, Carbon, Proton, Growth, Country, Steam, Transport, Porter's five forces analysis, SWOT, ATR, Refrigeration, Carbon footprint, CBAM, European, Hydrogen, SMR, Chemical industry, Alkaline water electrolysis, USD, Fertilizer, Power, Mining

The Global Low Carbon Ammonia market showcased growth at a CAGR of 46.98% during 2022-2025.

Key Points: 
  • The Global Low Carbon Ammonia market showcased growth at a CAGR of 46.98% during 2022-2025.
  • The report analyses the Low Carbon Ammonia Market by Region (Americas, Europe, Asia Pacific, Middle East & Africa) and 10 Countries (United States, Canada, Brazil, Germany, United Kingdom, France, China, Japan, South Korea, and India).
  • Japan and South Korea have set ambitious targets for the use of low carbon hydrogen and ammonia in their national energy strategies.
  • The report analyses the Low Carbon Ammonia Market By End-Use (Industrial Feedstock, Power Generation, Transportation, and Other End-Uses).

Radix Launches Resident Portal to Deliver Pricing Data to Renters

Retrieved on: 
Tuesday, April 2, 2024
Research, ATR, Advertising, AI

SCOTTSDALE, Ariz., April 2, 2024 /PRNewswire-PRWeb/ -- Radix, a pioneer in multifamily market research, performance, and data analytics, announces the launch of its Radix Resident Portal, a groundbreaking public data platform aimed at enhancing consumer visibility into property data.

Key Points: 
  • SCOTTSDALE, Ariz., April 2, 2024 /PRNewswire-PRWeb/ -- Radix , a pioneer in multifamily market research, performance, and data analytics, announces the launch of its Radix Resident Portal, a groundbreaking public data platform aimed at enhancing consumer visibility into property data.
  • "Our aim with the resident portal is to empower consumers with enhanced market visibility, illuminate prevailing concessions, and champion economic empowerment," remarked Radix CEO Blerim Zeqiri.
  • In a bid to foster economic liberty while making markets more dynamic, Radix champions data accessibility, dismantling the barriers that hinder market efficiency.
  • Now, with the introduction of the Radix Resident Portal, renters gain access to this invaluable data, facilitating streamlined price discovery, spotlighting concessions and discounts, and facilitating the discovery of rental options tailored to their specific needs.

Aprea Therapeutics Announces Private Placement Financing of up to $34.0 Million

Retrieved on: 
Monday, March 11, 2024
Cyclin, Exchange, Prospectus, APRE, DNA, Cyclin E, Sale, Breast, WEE1, DDR, Therapy, Patient, United, Security (finance), IND, Synthetic lethality, ATR, VWAP

DOYLESTOWN, Pa., March 11, 2024 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical-stage biopharmaceutical company focused on precision oncology through synthetic lethality, today announced that it has entered into a securities purchase agreement with new and existing healthcare focused institutional investors and certain Company insiders to raise up to $34.0 million in gross proceeds, including initial upfront funding of $16.0 million and up to an additional $18.0 million upon cash exercise of accompanying warrants at the election of the investors.

Key Points: 
  • “This meaningful financing led by high quality healthcare institutions will support Aprea in our goal to be a leader in the field of Synthetic Lethality (SL) and DNA Damage and Response (DDR),” said Dr. Oren Gilad, President and CEO of Aprea.
  • The private placement is expected to close on or about March 13, 2024 subject to satisfaction of customary closing conditions.
  • Aprea intends to use the upfront net proceeds from the private placement for general corporate purposes and to fund clinical development of APR-1051, the Company’s WEE1 inhibitor product candidate which recently received IND clearance.
  • Any offering of the securities under the resale registration statement will only be made by means of a prospectus.

Bragar Eagel & Squire, P.C. Is Investigating Thoughtworks, Chemours, Methanex, and Inari Medical and Encourages Investors to Contact the Firm

Retrieved on: 
Saturday, March 9, 2024
The Company, Investigation, Acquisition, Methanex, Annual report, CID, News, Chemours, Audit committee, Justice, Thoughtworks, G3, Security (finance), Methanol, Meal, Bank statement, ATR, CC, P.C

Our investigations concern whether these companies have violated the federal securities laws and/or engaged in other unlawful business practices.

Key Points: 
  • Our investigations concern whether these companies have violated the federal securities laws and/or engaged in other unlawful business practices.
  • For more information on the Chemours investigation go to: https://bespc.com/cases/CC
    On February 20, 2024, Methanex issued a press release “announc[ing] .
  • The CID requests information and documents primarily relating to meals and consulting service payments provided to health care professionals (“HCPs”).
  • For more information on the Inari Medical investigation go to: https://bespc.com/cases/NARI